---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-051526"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:32:22.509226+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences cuts workforce 41%, appoints Christopher Kirk as CEO, extends cash runway to late 2026

## Summary
- Workforce reduction of ~41%, pausing all research and drug discovery; severance charge of $2.9M-$3.2M expected in Q4 2023.
- CEO John Fowler resigns Nov 7; co-founder Christopher Kirk appointed CEO with $600k salary, $75k bonus, 875k stock options.
- CMO Noreen Roth Henig steps down Oct 6; Zung To assumes clinical operations oversight.
- Cash runway extended to late 2026; PALIZADE Phase 2b LN data mid-2026. KZR-261 Phase 1 data 2024, PORTOLA AIH data mid-2025.
- Exploring strategic partnering for protein secretion platform and preclinical programs.

## SEC filing metadata
- accession: 0000950170-23-051526
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017023051526/0000950170-23-051526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017023051526/kzr-20230930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-051526
- JSON: https://secwatch.observer/filing/0000950170-23-051526.json
- Plain text: https://secwatch.observer/filing/0000950170-23-051526.txt

## Key facts
- Executive change
  Christopher Kirk was appointed as Chief Executive Officer at Kezar Life Sciences, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Christopher Kirk, Ph.D., the Company’s co-founder and member of the Board, has been appointed to serve as Chief Executive Officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017023051526/0000950170-23-051526-index.htm
- Executive change
  John Fowler resigned as Chief Executive Officer at Kezar Life Sciences, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On September 30, 2023, John Fowler, the Company’s co-founder, Chief Executive Officer and member of the Board, notified the Board that he will resign and cease serving as Chief Executive Officer, effective November 7, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017023051526/0000950170-23-051526-index.htm
- Restructurings & Charges
  Kezar Life Sciences, Inc. announced a impairment affecting research and drug discovery activities.
  - Type: impairment
  - Affected area: research and drug discovery activities
  source text: The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction, including potential impairment charges due to the pausing of the Company’s research and drug discovery activities. However, the Company is not able to estimate the amount or range of amounts of such potential impairments as of the date of this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017023051526/0000950170-23-051526-index.htm
- Restructurings & Charges
  Kezar Life Sciences, Inc. announced a restructuring with charges of approximately $2.9 million to $3.2 million (approximately 41%).
  - Type: restructuring
  - Charge: approximately $2.9 million to $3.2 million
  - Headcount: approximately 41%
  source text: will pause all research and drug discovery activities. The Company anticipates the one-time severance-related charge associated with the workforce reduction to be approximately $2.9 million to $3.2 million. The severance-related charge, which is expected to represent cash expenditures that the Company expects to incur in connection with the workforce reduction, are
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017023051526/0000950170-23-051526-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.